GRANTS / FUNDING

Funding for Phase 1 & 2

WP1122 has received nearly $2 million in grants and has had over $1 in development dollars invested in furthering the technology and expects to spend over $2 million in the next 24 months on Phase I and Phase II clinical trials.

 

 

REGULATORY

WP1122 expected to have a completed IND and begin clinical trials in 2019

DRUG DISCOVERY & DEVELOPMENT

Additional Indications

UT MD Anderson Cancer Center
Ranked in the USA as No 1 cancer treatment and research center and the leading institution in the world, drug discovery.

Moleculin Biotech, Inc.
Drug development

University of Bergen, Norway
Drug development

CLINICAL DEVELOPMENT

Preclinical Development

ALS through its development partner has shown in preclinical trials that WP1122 performed as well or better than temozolomide, a drug that is a standard of care for the treatment of glioblastoma.

INDICATIONS

Subsequent Studies

Pancreatic Cancer & Glioblastoma. Combination with radiotherapy

OTHER INDICATIONS

Additional Indications

A combination of WP1122 with cytotoxic agents should produce significantly enhanced anticancer effects in a wide range of cancers.